Are Peptides Legal in Germany?

Buying a peptide in Germany can potentially violate one law, both laws, or neither – depending on what was purchased, how it was labelled, where it came from, and why the buyer acquired it. The two statutes governing this are the Arzneimittelgesetz (AMG, Medicinal Products Act) and the Anti-Doping-Gesetz (AntiDopG), which serve different purposes but overlap in practice.

The Arzneimittelgesetz (AMG) – Medicinal Products Act

The Arzneimittelgesetz (AMG) is Germany’s national pharmaceutical law, most recently amended by the Act of 23 October 2024 (Federal Law Gazette 2024 I no. 324), with Article 1 entering into force on 30 October 2024 and Article 2 on 1 July 2025. Under Section 2(1) of the AMG, a substance is a medicinal product if it is intended for use in or on the human body for curing, alleviating, or preventing diseases or disease symptoms, or for restoring, correcting, or modifying physiological functions. This definition mirrors the EU’s Directive 2001/83/EC but is implemented and enforced at the national level by the Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM), headquartered in Bonn.

The BfArM employs approximately 1,002 staff and operates with an annual budget of roughly EUR 142 million (2026 figures). It is responsible for marketing authorisations, pharmacovigilance, and regulatory oversight of all medicinal products marketed in Germany. For peptides, the BfArM’s role is straightforward: any peptide marketed or sold as a treatment, remedy, or modifier of physiological function in humans requires a marketing authorisation (Zulassung) before it can be legally placed on the German market.

Peptides with valid German marketing authorisations include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), liraglutide (Victoza, Saxenda), teriparatide (Forsteo), octreotide, and somatropin – all holding centralised EMA authorisations valid across the EU. BPC-157, TB-500, CJC-1295, Ipamorelin, Semax, Selank, and the majority of research peptides have no BfArM authorisation, no pending application, and are not registered as medicinal products in Germany.

Section 73 of the AMG governs the importation of medicinal products. Importing an unauthorized medicinal product into Germany – even for personal use – can constitute an AMG violation if the product is classified as a drug under Section 2. The “research use only” label does not override this classification if the surrounding context (vendor website, marketing, dosing information) implies therapeutic intent. As German legal commentators have noted, the decisive factor is not the label but how the substance is classified under the AMG – and this classification is determined by the authorities, not by the vendor.

The bottom line: Under the AMG, whether a peptide is a “medicinal product” depends on its intended purpose and positioning, not its chemical structure – the same compound can be a research chemical or an unauthorized drug depending on how it is presented.

The Anti-Doping-Gesetz (AntiDopG)

The Anti-Doping-Gesetz, which entered into force on 18 December 2015, is Germany’s national criminal anti-doping law. It is distinct from the AMG and introduces criminal penalties – not just administrative consequences – for doping-related activities. The AntiDopG was the first German law to make self-doping a punishable criminal offence, going further than most other EU member states.

The substances covered by the AntiDopG are listed in its Annex, which references the International Convention against Doping in Sport. Substances prohibited at all times include anabolic agents, peptide hormones, growth factors, related substances and mimetics, and hormone and metabolic modulators. This means that peptide hormones as a class – including HGH, IGF-1, GHRPs, growth hormone-releasing hormones (GHRH), and growth hormone secretagogues – fall within the AntiDopG’s scope when acquired or possessed for doping purposes.

The criminal penalties under Section 4 of the AntiDopG are significant. Manufacturing, trafficking, or administering doping substances carries up to three years’ imprisonment. Acquiring or possessing doping substances in “not small” quantities for self-doping carries up to two years’ imprisonment. In aggravated cases – such as supplying to minors, acting commercially, or operating as part of an organised group – penalties escalate to between one and ten years’ imprisonment. The Doping Substances (Quantities) Regulation (DmMV) defines what constitutes a “not small” quantity, and the thresholds are strict.

The AntiDopG criminalises importation as a distinct offence. Doping substances are “imported” when they are physically brought across national borders – whether through personal transport, postal shipments, or courier services. German customs (Zoll) authorities routinely monitor and intercept suspected doping agents at airports, border crossings, and mail processing centres, and interceptions can trigger criminal investigations.

The bottom line: The AntiDopG creates criminal liability for possessing peptide hormones and growth factors for doping purposes – even in small quantities, even for personal use, and even for recreational sport.

Most research peptides are not scheduled under Germany’s Narcotics Act (Betaubungsmittelgesetz, BtMG), but the statute is relevant when compounds with anabolic properties are involved. The BtMG regulates controlled substances through three annexes: Anlage I (authorised scientific use only, not prescriptible), Anlage II (authorised trade only, not prescriptible), and Anlage III (prescriptible via special prescription form). BPC-157, TB-500, CJC-1295, and most commonly discussed peptides do not appear in any BtMG annex. However, any compound that bridges the peptide-steroid boundary or has anabolic properties may attract scrutiny under both the BtMG and the AntiDopG.

The BtMG is enforced by the Bundesopiumstelle (Federal Opium Agency), which sits within the BfArM. For peptides, the BtMG is less relevant than the AMG and AntiDopG, but it is important to note that some compounds marketed alongside peptides in the biohacking community – such as certain SARMs, synthetic cannabinoids, and nootropics – may be BtMG-scheduled, and a package containing both peptides and BtMG-scheduled substances would face criminal-law consequences for the controlled substance even if the peptides themselves are not BtMG-listed.

The legality of purchasing a specific peptide in Germany depends on three factors: whether it is scheduled under the BtMG, whether it falls within the AntiDopG’s doping substance categories, and whether it is positioned as a medicinal product under the AMG. The following table summarises the status of commonly discussed compounds.

Compound	BtMG Status	AntiDopG Relevance	AMG Status	Research Purchase
BPC-157	Not scheduled	Not a peptide hormone/GF	No Zulassung	Legal for research
TB-500	Not scheduled	Potential (growth factor)	No Zulassung	Legal for research; doping risk if for sport
CJC-1295	Not scheduled	Yes (GHRH analogue)	No Zulassung	Legal for research; AntiDopG risk if for doping
Ipamorelin	Not scheduled	Yes (GH secretagogue)	No Zulassung	Legal for research; AntiDopG risk if for doping
HGH (Somatropin)	Not scheduled	Yes (peptide hormone)	Zulassung (Rx only)	Rx only. Criminal penalties for trafficking/doping possession.
Semax / Selank	Not scheduled	Not a peptide hormone/GF	No Zulassung	Legal for research
Melanotan II	Not scheduled	Not a peptide hormone/GF	No Zulassung. Unauthorized.	AMG risk if positioned therapeutically. No BtMG/AntiDopG issue.
Semaglutide	Not scheduled	Not a peptide hormone/GF	Zulassung (Rx only)	Rx from Apotheke only. Unauthorized versions are AMG violations.

The key distinction is between peptides that are merely unauthorized drugs (AMG issue only) and those that also qualify as doping substances (AMG + AntiDopG issue). BPC-157, for example, is not classified as a peptide hormone, growth factor, or hormone modulator under the AntiDopG’s Annex – it is a gastric pentadecapeptide with no direct growth hormone or anabolic mechanism. This places BPC-157 in the AMG-only category: it is an unauthorized drug if sold for therapeutic use, but purchasing it for research does not trigger AntiDopG criminal liability. CJC-1295 and Ipamorelin, by contrast, are growth hormone-releasing hormone analogues and growth hormone secretagogues respectively, placing them squarely within the AntiDopG’s “peptide hormones, growth factors, related substances and mimetics” category.

The bottom line: In Germany, the AntiDopG adds criminal liability on top of AMG administrative violations for any peptide that qualifies as a doping substance under WADA categories – and the threshold for “not small” quantities is deliberately low.

German customs authorities (Zollverwaltung) are the primary enforcement interface for individuals importing peptides. The Zoll operates at airports, land borders, and postal/courier processing centres and has the authority to open, inspect, and seize packages suspected of containing unauthorized medicinal products or doping substances.

For packages entering Germany from non-EU countries – the United States, China, India, or the UK (post-Brexit) – Zoll inspection is a real possibility. Shipments containing unlabelled vials, lyophilised powders, or products with insufficient documentation are routinely flagged. When a seizure occurs, the recipient typically receives a written notice (Bescheid) from the Zoll citing the specific legal basis – usually an AMG Section 73 violation for unauthorized medicinal product importation. Recipients have 14 days to respond. If the product also falls within the AntiDopG’s scope, the case may be referred to the Staatsanwaltschaft (public prosecutor’s office) for criminal investigation.

Germany participated in Europol’s Operation SHIELD VI (April-November 2025), which seized EUR 33.17 million in illicit medicines and doping substances across 30 countries. German-specific enforcement within the operation included investigations into groups reselling legally obtained prescription medicines through online shops and darknet platforms. For a broader overview of Operation SHIELD VI and EU-level enforcement, see our guide to peptide legality in the EU.

Germany conducted approximately 12,100 doping controls in 2024, producing nearly 16,400 samples. The NADA (Nationale Anti-Doping Agentur) coordinates testing across all sports, with football (over 800 training and 1,000 competition controls), cycling (approximately 1,000 training and 580 competition controls), and athletics among the most heavily tested disciplines. Athletes who test positive for peptide hormones face prosecution under the AntiDopG in addition to sporting sanctions.

The bottom line: The Zoll is the enforcement front line for peptide imports from non-EU countries – but intra-EU shipments bypass customs entirely, creating a regulatory architecture where the source country matters as much as the substance.

Germany has a strong Apothekenpflicht (pharmacy obligation) tradition. Prescription medications must be dispensed through licensed Apotheken, and the pharmaceutical supply chain is tightly controlled. Unlike the United States, Germany does not have a distinct 503A/503B compounding pathway. For an explanation of the US compounding system, see our guide to FDA Category 1 vs Category 2.

Under Section 13 of the AMG, German pharmacies can prepare custom-formulated medications (Rezepturarzneimittel) on a patient-specific basis with a valid physician prescription. This includes certain compounded peptide preparations – for example, topical GHK-Cu formulations or specific peptide combinations prepared for individual patients by a dispensing pharmacist. However, this pathway is narrow: it requires a specific prescription, a licensed Apotheke, and compliance with pharmaceutical manufacturing standards. Bulk production of non-authorized peptide formulations for general sale is not permitted under this framework.

The Heilmittelwerbegesetz (HWG) adds another layer. This is Germany’s Act on the Advertising of Therapeutic Products, which restricts how medicinal products – including unauthorized ones – can be promoted. A vendor advertising peptides with health claims, therapeutic benefits, or performance enhancement effects to a German audience is violating the HWG regardless of where the vendor is based. The HWG covers advertising directed at both healthcare professionals and the general public, and enforcement can include fines, injunctions, and criminal prosecution.

Offence	Legal Basis	Maximum Penalty
Trafficking doping substances	AntiDopG Section 4(1)	3 years’ imprisonment or fine
Self-doping (possession for sport)	AntiDopG Section 4(2)	2 years’ imprisonment or fine
Supplying doping substances to minors	AntiDopG Section 4(4)(a)	1-10 years’ imprisonment
Commercial/gang trafficking of doping	AntiDopG Section 4(4)(b)	1-10 years’ imprisonment
Negligent doping offence	AntiDopG Section 4(6)	1 year’s imprisonment or fine
Importing unauthorized medicinal product	AMG Section 73 / Section 95-97	Fine or up to 1 year (administrative offence); up to 3 years if commercial
Advertising unauthorized medicines	HWG	Fine; criminal prosecution in aggravated cases

Factor	Germany	United States	United Kingdom
Primary law	AMG + AntiDopG (dual)	FD&C Act	HMR 2012 + MDA 1971
Self-doping criminal?	Yes (since 2015)	No	No
Personal possession (non-doping)	AMG administrative risk only	Not criminal	Not criminal (non-Class C)
Compounding pathway	Narrow (AMG Section 13, Apotheke only)	Broad (503A/503B)	Limited (no equivalent pathway)
Import customs risk	High (non-EU) / None (intra-EU)	Moderate (CBP)	Moderate (Border Force)
Advertising restrictions	Strict (HWG applies to all advertising)	FTC enforcement (increasing)	MHRA + ASA enforcement

Germany is unique among major Western countries in criminalising self-doping. Neither the United States, the United Kingdom, nor Australia treats personal use of doping substances as a criminal offence in itself (though trafficking and supply are criminal in all four jurisdictions). The AntiDopG was controversial when adopted in 2015 and the German Federal Government commissioned a formal evaluation of its practical application five years after enactment. The law remains in force and continues to be actively enforced. For a detailed comparison with the UK’s three-law framework, see our guide to peptide legality in the UK.

The transposition of the new EU pharmaceutical Directive (agreed December 2025, final texts published March 2026) will require Germany to update the AMG over the next approximately 36 months. While the new framework primarily affects marketing authorisation holders and pharmaceutical companies, it will modernise the legal architecture that governs how peptide medicines are approved and made available in Germany.

The EMA’s new guideline on synthetic peptide manufacturing (effective 1 June 2026) applies to pharmaceutical manufacturers seeking marketing authorisations, not to research chemical suppliers. However, Germany – as the reference member state in the landmark CJEU Case C-118/24 on synthetic peptide generics – is positioned at the centre of how the EU’s evolving peptide regulatory framework develops in practice.

The counterfeit semaglutide problem is particularly acute in Germany given the high demand for GLP-1 medications and the tight prescribing pathway through the Kassenarztliche Vereinigung (association of statutory health insurance physicians). As legitimate supply struggles to meet demand, the market for unauthorized and counterfeit GLP-1 products grows – and with it, Zoll and BfArM enforcement activity.